Greg Salsburg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesIlanit allenGreg salsburgExchange commissionHc wainwright coPrnewswire citius pharmaceuticals incCitius pharmaceuticals announces closingSecurities exchangeCitius pharmaceuticals incPharmaceuticals announces closingRegistered directCitius pharmaceuticalsBiologics license applicationCitius oncologySecurities act

Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

/PRNewswire/ Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and.

New yorkUnited statesGreg salsburgIlanit allenCitius pharmaceuticals incExchange commissionHc wainwright coSecurities exchangeCitius pharmaceuticalsBiologics license applicationCitius oncologySecurities actSecurities exchange actAnnual report

Citius Pharmaceuticals Announces Addition of City of Hope to UMN s Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing.

United statesUniversity of minnesotaOrange countyMatthew meiCitius pharmaMyron czuczmanIlanit allenGreg salsburgVeronika bachanovaLos angelesUniversity of minnesota masonic cancer centerMasonic cancer centerPrnewswire citius pharmaceuticals incExchange commissionNovartis pharmaceuticals corporationCancer center

Citius Pharmaceuticals, Inc : Citius Pharmaceuticals Announces Addition of City of Hope to UMN s Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

Citius Pharmaceuticals, Inc : Citius Pharmaceuticals Announces Addition of City of Hope to UMN s Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUniversity of minnesotaOrange countyLos angelesIlanit allenMyron czuczmanMatthew meiVeronika bachanovaGreg salsburgDennis riedlCitius pharmaKite pharma incUniversity of minnesota masonic cancer centerCompany nasdaqSecurities exchangeTranslational genomics research institute

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development.

Greg salsburgCitius pharmaIlanit allenCompany biologics license applicationExchange commissionCitius pharmaceuticals incSecurities exchangeCompany nasdaqPrnewswire citius pharmaceuticals incDrug administrationInvestor relations for citius pharmaceuticalsPrescription drug user fee actBiologics license applicationComplete response letterDrug evaluationCitius pharmaceuticals